Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition

Circulation

Volumn 96, Issue 4, 1997, Pages 1250-1256

  Donckier, Julian E ^a   Massart, Pierre Emmanuel ^b   Hodeige, Dominique ^b   Van Mechelen, Henri ^b   Clozel, Jean Paul ^d   Laloux, Olivier ^b   Ketelslegers, Jean Marie ^b   Charlier, André A ^b   Heyndrickx, Guy R ^b,c  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c CARDIOVASCULAR CENTER   (Belgium)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Angiotensin; Endothelin; Enzymes; Hypertension; Vasodilation

Indexed keywords

BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG VEHICLE; ENALAPRILAT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME INHIBITION; HEART LEFT VENTRICLE PRESSURE; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; VASODILATATION;

EID: 0030861322     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.4.1250     Document Type: Article

References (28)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayaski M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
2. Donckier JE, Hanet C, Berbinschi A, Galanti L, Robert A, Van Mechelen H, Pouleur H, Ketelslegers J. Cardiovascular and endocrine effects of endothelin-1 at pathophysiological and pharmacological plasma concentrations in conscious dogs. Circulation. 1991;84:2476-2484.
3. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S. Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol. 1990;258:C408-C415.
4. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle. Atherosclerosis. 1989;78: 225-228.
5. Haynes W, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852-854.
6. Clozel M, Breu V, Burri K, Cassai JM, Fischli W, Gray GA, Hirth G, Löffler BM, Müller M, Neidhart W, Ramuz H. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993;365:759-761.
7. Grover G, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduced infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res. 1993;27:1613-1618.
8. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346: 732-736.
9. Kohno M, Yasunari K, Murakawa KI, Yokokawa K, Horio T, Fukui T, Takeda T. Plasma immunoreactive endothelin in essential hypertension. Am J Med. 1990;88:614-618.
10. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens. 1991;4:303-308.
11. Schiffrin EL, Deng LY, Larochelle P. Blunted effects of endothelin upon small subcutaneous resistance arteries of mild hypertensive patients. J Hypertens. 1992;10:434-444.
12. Lüscher T, Seo B, Buhler R. Potential role of endothelin in hypertension. Hypertension. 1993;21:752-757.
13. Li JS, Larivière R, Schiffrin E. Effect of a nonselective endothelin antagonist on vascular remodeling in DOCA-salt hypertensive rats. Hypertension. 1994;24:183-188.
14. Li J, Schiffrin E. Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. J Hypertens. 1995;13: 647-652.
15. Donckier JE, Stoleru L, Hayashida W, Van Mechelen H, Selvais P, Galanti L, Clozel J, Ketelslegers J, Pouleur H. Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation. 1995;92:106-113.
16. Page IH. The production of persistent arterial hypertension by cellophane perinephritis. JAMA. 1939;113:2046-2048.
17. Sweet CS. Pharmacological properties of the converting enzyme inhibitor, enalaprilat maleate (MK-421). Fed Proc. 1983;42:167-170.
18. Sansdrap J, Van Mechelen H, Pouleur H, Charlier AA. CROPA: a research-oriented program for automatic processing of cardiovascular signals. In: Computers in Cardiology. Florence, Italy: IEEE Computer Society; 1981:433-436.
19. Donckier JE, Hanet C, Galanti L, Stoleru L, Van Mechelen H, Robert A, Ketelslegers J, Pouleur H. Low-dose endothelin-1 potentiates volume-induced secretion of atrial natriuretic factor. Am J Physiol. 1992;263:H939-H944.
20. Berbinschi A, Ketelslegers JM. Endothelin in urine. Lancet. 1989; 1:909. Letter.
21. Breu V, Clozel M, Löffler B. In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett. 1993;334:210-214.
22. Kohno M, Yasunari K, Yokokawa K, Murakawa K, Horio T, Takeda T. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured hormone endothelial cells. J Clin Invest. 1991; 87:1999-2004.
23. Kohno M, Horio T, Ikeda M, Yokokana K, Fukui T, Yasunari K, Kurihara N, Takeda T, Johchi M. Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int. 1992;42:860-866.
24. Urata H, Healy B, Stewart RW, Bumpus M, Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
25. Masaki T. Endothelins: homeostatic and compensatory actions in the circulatory and endocrine systems. Endocr Rev. 1993;14: 256-268.
26. Schiffrin EL, Larivière R, Li J, Sventek P, Touyz R. Deoxycorticosterone acetate plus salt induce overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension. 1995;25:769-773.
27. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ET-B receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-1465.
28. Kaufmann H, Oribe E, Oliver J. Plasma endothelin during upright tilt relevance for orthostatic hypertension? Lancet. 1991;338: 1542-1545.